
    
      The primary objective of this study is to compare the change in exercise capacity following
      treatment with cicletanine HCl or placebo in subjects with PAH.

      The secondary objectives of this study are:

        1. To compare the change in other clinical measures of PAH following treatment with
           cicletanine HCl or placebo in subjects with PAH

        2. To compare the safety and tolerability of cicletanine HCl to placebo in subjects with
           PAH Additionally, the long-term safety, tolerability, and efficacy of cicletanine HCl
           treatment will be evaluated.
    
  